Jazz Pharmaceuticals (JAZZ) As HER2 Pipeline Progress Fuels An Undervalued Narrative
Jazz Pharmaceuticals (JAZZ) is gaining investor attention due to its HER2 pipeline progress, particularly for gastroesophageal adenocarcinoma, and is currently deemed 11.6% undervalued with a fair value of $281.35. Despite a recent share price pullback, the company shows strong year-to-date and one-year returns, driven by R&D, commercialization efforts, and international expansion, although potential risks like generic pressure and trial underperformance exist.
Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target
Harrow Inc. (HROW) faces a significant challenge to meet its full-year revenue guidance of $350 million to $365 million after a softer first half. Despite strong product momentum in IHEEZO, VEVYE, and TRIESENCE, and an upcoming acquisition of TYRVAYA, the company needs to generate $235 million to $250 million in the second half, compared to $115 million in the first. Wall Street remains skeptical, with high short interest and a forward P/E ratio that already prices in substantial growth.
This Monthly Dividend ETF Pays $2,260 a Year on a $100,000 Stake From Mid-Caps Income Investors Skip
The WisdomTree U.S. MidCap Dividend Fund (DON) offers a unique approach for income investors by targeting dividend-paying mid-cap companies, providing a monthly distribution, and yielding 2.26% ($2,260 annually on a $100,000 investment). Unlike many large-cap and option-income ETFs, DON focuses on actual dividends from a diversified portfolio with significant exposure to financials and industrials, rather than being technology-heavy. This makes DON an attractive complement for portfolios already concentrated in large-cap growth stocks, offering diversification and consistent income from a segment often overlooked by investors.
3 Stocks Under $50 We’re Skeptical Of
This article highlights three stocks priced under $50—Central Garden & Pet (CENT), Bausch + Lomb (BLCO), and Viatris (VTRS)—that StockStory is skeptical about due to concerning financial trends like declining sales, negative EPS growth, and poor returns on capital. The author provides specific reasons for caution regarding each company and suggests investors look for better opportunities, also promoting StockStory's "Strong Momentum Stocks" as an alternative.
Theravance Biopharma Deal Faces Investor Probe
Halper Sadeh LLC is investigating the proposed acquisition of Theravance Biopharma (NASDAQ: TBPH) by Zymeworks Inc. for $17 per share in cash plus a contingent value right. The investigation aims to determine if Theravance shareholders are receiving a fair price and if the company's board fulfilled its fiduciary duties. Theravance maintains that the deal offers significant value, representing a premium over its stock price before the acquisition announcement.
Wall Street Zen Upgrades Harrow (NASDAQ:HROW) to "Hold"
Wall Street Zen has upgraded Harrow (NASDAQ:HROW) from "sell" to "hold," though overall analyst sentiment remains a "Moderate Buy" with a target of $69.43. This comes as Harrow reported a quarterly loss that missed estimates despite slightly exceeding revenue expectations. Institutional investors hold a significant portion of the company's stock, and an insider recently purchased shares, while potential growth from new product commercialization is balanced against lowered earnings forecasts and ongoing profitability concerns.
Lexicon Pharmaceuticals (LXRX) Completes Phase III Enrollment, Is The 38% Undervaluation Case Convincing?
Lexicon Pharmaceuticals (LXRX) has completed enrollment in its Phase III SONATA HCM trial for sotagliflozin, with positive momentum from regulatory updates and partner collaborations. The company is considered 38% undervalued by some narratives, trading at $2.34 against a fair value of $3.77 per share, based on future earnings and pipeline potential. However, a high P/S ratio of 25.1x suggests significant valuation risk if revenue growth or margin expectations are not met.
Viatris Inc. stock rises Friday, outperforms market
Viatris Inc. (VTRS) stock increased by 1.18% to $16.23 on Friday, despite a general market downturn where the S&P 500 Index and Dow Jones Industrial Average both saw declines. This gain ended a two-day losing streak for Viatris, indicating a resilient performance against broader market trends.
Jazz Pharmaceuticals (JAZZ) Stock Looks Cheap On Earnings While Broader Checks Stay Mixed
Jazz Pharmaceuticals (JAZZ) stock has shown a significant return of 112.6% over the past year. Despite this performance and recent deal activity, the stock appears undervalued based on its P/E ratio of 17.2x, which is on par with the industry average but significantly lower than a peer group average of 28.8x and its estimated fair P/E of 24.7x. The market's current valuation of JAZZ suggests a mixed picture, not a clear bargain, with the company's ability to execute on its pipeline and manage risks being key to future performance.
Viatris Inc. stock falls Wednesday, underperforms market
Viatris Inc. (VTRS) shares fell by 1.11% on Wednesday, closing at $16.10, underperforming the broader market. The S&P 500 Index saw a gain of 0.26%, while the Dow Jones Industrial Average slightly declined by 0.04%. Viatris Inc. is now trading 12.45% below its 52-week high.
Davis Selected Advisers (VTRS) discloses 75.2M-share, 6.5% stake in Viatris Inc
Davis Selected Advisers has reported a beneficial ownership of 75,232,254 shares, representing a 6.5% stake in Viatris Inc. The firm holds sole voting power over 72,567,897 shares and sole dispositive power over all 75,232,254 shares. This disclosure, filed as a Schedule 13G/A, indicates Davis Selected Advisers as a significant institutional holder of Viatris common stock.
ETFs Investing in Viatris, Inc. Stocks
This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold Viatris, Inc. (VTRS) stocks, sorted by market value. It details various ETFs, including their issuer, management style, focus, expense ratio, assets under management (AUM), and 3-year NAV total return. The ETFs listed range from broad market funds to sector-specific healthcare and pharmaceutical funds, offering investors diverse options to gain exposure to Viatris, Inc.
Viatris Inc. (VTRS) Stock Price, News, Quote & History
This Yahoo Finance page provides a comprehensive overview of Viatris Inc. (VTRS) stock, including its current price, dividend information, and a collection of recent news articles. The news highlights Viatris's Q2 earnings performance, strategic moves like selling Tyrvaya, and analyst insights on its valuation and growth prospects, particularly in China. The page also includes performance metrics comparing VTRS to the S&P 500.
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks
Theravance Biopharma (TBPH) reported Q2 2026 adjusted earnings matching estimates and slightly exceeding revenue expectations. The company is set to be acquired by Zymeworks (ZYME) for approximately $929 million in an all-cash transaction, following the discontinuation of its lead candidate ampreloxetine and a subsequent strategic review and restructuring. The acquisition is viewed as the most value-maximizing option for shareholders, with Theravance also implementing significant cost-cutting measures.
Theravance Biopharma, Inc. 2026: Revenue $20.73M, EPS ($0.11) — 10-Q Summary
Theravance Biopharma, Inc. (TBPH) reported its 2026 quarterly results, showing a significant decrease in revenue and a net loss compared to the prior year. Revenue dropped by 20.9% to $20.73M, resulting in a diluted EPS of ($0.11) versus $1.08 previously, largely due to the failure of the ampreloxetine Phase 3 trial and subsequent restructuring. The company is undergoing a strategic shift with a merger agreement with Zymeworks and a significant reduction in operating expenses.
VTRS Q2 Deep Dive: China Growth, Pipeline Progress, and Margin Concerns Shape Outlook
Viatris (VTRS) reported better-than-expected Q2 CY2026 revenue and non-GAAP profit, driven by strong commercial execution in Greater China and demand for cardiovascular products. Despite this, the company faced a negative market reaction due to supply chain disruptions and lower-margin products in emerging markets. Management highlighted new product launches and cost containment as key to their updated full-year guidance, while acknowledging challenges from manufacturing disruptions and policy changes in China.
Viatris (VTRS) Stock Trades At A Discount To Sales Despite A 76% Run
Viatris (VTRS) stock has seen a 76.1% gain over the past year, yet remains undervalued according to various valuation checks, trading at a discount to sales compared to its industry peers. The recent FDA approval for Gwyn Lo contraceptive patch and the planned sale of TYRVAYA nasal spray rights introduce both positive and uncertain factors for its future revenue. While some investors see deep value, others are cautious about potential margin compression in its core generics business.
Harrow Achieves Q2 Revenue Growth, Reiterates 2026 Full-Year Financial Guidance
Harrow announced its financial results for the second quarter ended June 30, 2026, reporting revenue of $70.7 million, a 60 percent sequential increase. The company reiterated its full-year 2026 financial guidance of $350 million to $365 million in revenue and $80 million to $100 million in adjusted EBITDA. Key developments include the commercial launch of Byooviz and the acquisition of Tyrvaya, positioning Harrow for accelerated growth.
Oculis Announces Asset Purchase Agreement With Accure Therapeutics, Posts Q2 2026 Financial Results
Oculis Holding AG has entered into an asset purchase agreement with Accure Therapeutics, acquiring global rights to Privosegtor, a neuroprotective drug candidate, for $3.8 million upfront and up to 2,050,000 Oculis shares. This strategic move follows the failure of Oculis's OCS-01 program in diabetic macular edema. The company also reported Q2 2026 financial results, including a net loss of CHF 38.8 million and cash reserves of CHF 228.3 million.
Theravance Biopharma Releases Q2 2026 Financial Results
Theravance Biopharma, Inc. (TBPH) reported mixed financial results for Q2 2026, with non-GAAP EPS of $0.11 and revenue of $20.7 million, down 20.9% year-over-year. Despite the revenue decline, the company achieved profitability with a net income of $9.5 million. The revenue was primarily driven by its key product, YUPELRI, which generated $20.7 million, an 11.0% increase from the previous year.
Harrow Announces Second Quarter 2026 Financial Results
Harrow (Nasdaq: HROW) announced its second-quarter 2026 financial results, reporting a quarterly revenue of $70.7 million, a 60% sequential increase and 11% year-over-year increase. The company reiterated its full-year 2026 revenue guidance of $350 million to $365 million and Adjusted EBITDA of $80 million to $100 million. Key product VEVYE® saw significant growth, and the company completed the acquisition of TYRVAYA® and launched BYOOVIZ®, strengthening its ophthalmic disease management portfolio.
Theravance Biopharma Releases Q2 2026 Financial Results
Theravance Biopharma (TBPH) reported mixed financial results for Q2 2026, with non-GAAP earnings per share of $0.11 and a net income of $9.5M, despite a 20.9% decline in revenue to $20.7M year-over-year. The company's key product, YUPELRI, generated $20.7M in revenue, showing 11.0% year-over-year growth. Wall Street analysts hold diverse views, with consensus at 4 buy and 5 hold ratings for the biopharmaceutical company.
Harrow adds TYRVAYA's global rights to dry eye portfolio
Harrow is expanding its dry eye product portfolio by acquiring the global rights to TYRVAYA (varenicline solution) nasal spray from Viatris, Inc. This FDA-approved nasal spray, indicated for dry eye disease, was originally developed by Oyster Point Pharma. The deal involves a $30 million upfront payment and up to $70 million in contingent milestone payments, complementing Harrow's existing dry eye product, VEVYE.
Theravance Biopharma Q2 2026: Viatris collaboration revenue $20.7M; net loss $5.9M; $388M cash
Theravance Biopharma reported its Q2 2026 financial results, including $20.7 million in revenue from its Viatris collaboration and a GAAP net loss of $5.9 million, with $387.7 million in cash and marketable securities. The company highlighted strong YUPELRI performance, a pending acquisition by Zymeworks, and significant cost reductions from organizational restructuring. They also expressed confidence in achieving a $100 million milestone payment from Royalty Pharma related to TRELEGY royalties.
Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Theravance Biopharma, Inc. announced its Q2 2026 financial results, highlighted by an 11% year-over-year increase in YUPELRI collaboration revenue and a significant 35% reduction in operating expenses due to restructuring. The company also confirmed its pending acquisition by Zymeworks for $17.00 per share cash plus a CVR, expected to close in the second half of 2026. Theravance Biopharma remains confident in achieving a $100 million milestone payment from Royalty Pharma based on TRELEGY net sales.
Why Viatris (VTRS) Is Down 6.4% After Boosting Guidance And Completing A $1.15 Billion Buyback
Viatris Inc. recently reported higher Q2 and year-to-date revenues, returned to net income, raised its full-year 2026 revenue guidance to US$14.75 billion, and completed a US$1.15 billion share repurchase program. Despite these positive developments, including a new FDA-approved contraceptive patch and reaffirmed dividend, the stock experienced a 6.4% decline. The article suggests that while the buyback improves per-share metrics, ongoing concerns about generic drug pricing pressure and regulatory reforms might be weighing on investor sentiment.
Viatris (VTRS) Is Down 6.4% After Raising 2026 Guidance And Completing Major Buyback Program
Viatris (VTRS) saw a 6.4% stock drop despite reporting increased second-quarter and year-to-date revenues, raising its 2026 earnings guidance midpoint to US$14.75 billion, and completing a significant US$1.15 billion share repurchase program. The company also affirmed a US$0.12 quarterly dividend and secured FDA approval for its Gwyn Lo contraceptive patch, indicating a dual focus on growth and shareholder returns. However, the article highlights persistent pricing and regulatory pressures as key risks that could erode margins despite new product launches and capital returns.
Viatris (VTRS) Stock Sees Modest Fair Value Lift After Q1 Results And Pipeline Progress
Viatris (VTRS) has seen a modest increase in its fair value estimate to US$18.50 per share following strong Q1 results and pipeline progress, leading Barclays to lift its price target to US$22 with an Overweight rating. While analysts are optimistic about the company's execution and upcoming product approvals, some caution that narrowing the revenue growth gap to peers may take time. The article highlights both bullish and bearish takes on Viatris's future and adjustments to its valuation metrics.
Results: Perrigo Company plc Exceeded Expectations And The Consensus Has Updated Its Estimates
Perrigo Company plc (NYSE:PRGO) shareholders saw a 27% increase in their stake following better-than-expected quarterly profits, despite revenues meeting analyst forecasts. While analysts reconfirmed revenue estimates for 2026, they significantly increased per-share loss predictions, though the consensus price target remained unchanged at US$16.50. The company's revenue is expected to decline by 4.1% annually through 2026, underperforming the industry's projected 9.2% annual growth.
AnaptysBio earnings ahead: Can royalty revenue offset spinoff volatility?
AnaptysBio, now operating as Anaptys, is set to report its Q2 results as a pure-play royalty management company after spinning off its drug development operations. Analysts project a loss of 13 cents per share on $20.2 million in revenue, with a significant improvement in EPS despite an expected revenue decline. Investors will focus on Jemperli royalty revenue trajectory, operating margin execution, and potential variability in royalty recognition.
Viatris Earnings: Good Performance in Key Regions and Outlook Increase Make for a Solid Quarter
Viatris reported a strong second quarter with 5% revenue growth and 11% adjusted earnings per share growth, both surpassing FactSet consensus estimates. The company also raised its EPS guidance by 5% at the midpoint, despite shares trading down 3% post-announcement. This performance highlights solid regional results and an improved outlook.
Kenvue Inc. (KVUE) Stock Forecasts
Kenvue Inc. (KVUE) is the world's largest pure-play consumer health company, having spun off from Johnson & Johnson in May 2023. Recent earnings show rare volume growth despite muted performance in the US and Europe. Analysts continue to evaluate its market position and financial outlook.
Harrow Enters Agreement to Acquire Tyrvaya Dry Eye Treatment From Viatris Inc.
Harrow has entered into a definitive agreement to acquire Tyrvaya (varenicline solution), a dry eye nasal spray treatment, from Viatris Inc. This acquisition aims to expand Harrow's dry eye portfolio, complementing its Vevye franchise by offering a differentiated treatment option with a distinct mechanism of action. The deal involves an upfront cash payment of $30 million and up to $70 million in contingent milestone payments, strengthening Harrow's position in the dry eye disease market.
Viatris Inc (VTRS) (Q2 2026) Earnings Call Highlights: Strong Growth and Raised Guidance Amid ...
Viatris Inc (VTRS) reported strong Q2 2026 results with $3.8 billion in revenues, a 3.5% operational growth year-over-year, and raised its full-year guidance. Key drivers included robust performance in Greater China and advancements in its R&D pipeline. The company also highlighted challenges such as supply disruptions at its Nashik facility and anticipated competitive pressures in developed markets, which are expected to temper growth in the second half of 2026.
Viatris Inc. Stock 12‑Month Price Target Raised to $18.71, Implies 6% Upside
Viatris Inc. (VTRS) has seen its average 12-month price target raised from $18.14 to $18.71 by 7 analysts, suggesting a 6% potential upside from its August 5th closing price. The consensus analyst rating remains a "Buy," with 5 out of 12 analysts recommending a Buy, 6 a Hold, and 1 a Sell.
Viatris Inc (VTRS) Shares Fall 7.6% -- GF Value Says Still Overvalued
Viatris Inc (VTRS) shares fell 7.6% to $16.29, which is still 47.7% above its GF Value of $11.03, indicating the stock is significantly overvalued. The company has a GF Score of 58/100, with weak growth potential, and recent insider selling further suggests a cautious outlook. Investors are advised to exercise caution due to the disparity between market price and intrinsic value.
Viatris Inc. stock falls Thursday, underperforms market
Viatris Inc. (VTRS) stock fell 7.71% to $16.29 on Thursday, marking its second consecutive day of losses. This decline occurred during a broader market downturn, with the S&P 500 Index and Dow Jones Industrial Average also experiencing losses.
HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
Halozyme Therapeutics, Inc. reported record second-quarter 2026 financial results, exceeding estimates and subsequently raising its full-year 2026 financial guidance. The company saw a 48% year-over-year increase in total revenue to $481 million, with royalty revenue growing 50% to $308 million, driven by the strong performance of its ENHANZE® partner products. Halozyme also expanded its collaboration agreements by signing five new ENHANZE® and Hypercon™ deals year-to-date and repurchased $333 million in shares.
Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook
Viatris announced it will sell its Tyrvaya nasal spray to Harrow Inc. for up to $100 million, a move designed to sharpen its focus on high-potential growth areas. The company also reported strong Q2 performance, beating analyst expectations for both earnings and sales, and subsequently raised its fiscal 2026 adjusted earnings and sales guidance.
Viatris Looks to New Launches, Pipeline Progression, and Cost Savings for Long-Term Growth
Viatris, one of the largest generic drug manufacturers globally, aims for long-term growth through new product launches, pipeline progression, and cost savings. While generics face erosion in developed markets, the company plans to focus on complex generics to mitigate pricing and margin pressures. This strategy is expected to drive future growth in a challenging market.
Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook
Viatris has agreed to sell its Tyrvaya nasal spray business to Harrow Inc. for up to $100 million, a move that will allow Viatris to focus on high-potential growth areas like complex generics and transdermal products, and continued investment in the Greater China market. Concurrently, Viatris reported strong second-quarter results, exceeding analyst expectations for both earnings and sales, and subsequently raised its fiscal 2026 adjusted earnings and sales guidance.
Viatris stock hits 52-week high at 18.27 USD
Viatris Inc. (VTRS) stock reached a 52-week high of $18.07, demonstrating strong investor confidence with a 109.7% return over the past year and a market capitalization of $20.55 billion. InvestingPro analysis suggests the stock is undervalued with a "GOOD" financial health score. Recent positive developments include strong Q1 2026 financial results, a successful Phase 3 clinical trial for VR-205, and FDA acceptance of a New Drug Application for a fast-acting meloxicam formulation.
Form 8K Viatris Inc For: 6 August By Investing.com
This article announces that Viatris Inc. has filed a Form 8K on August 6th. The filing is presented without additional details or commentary, focusing solely on the event itself. The article also includes stock performance for VTRS and links to other related market data.
FMR LLC discloses 8.3% Viatris Inc (VTRS) ownership, over 96M shares
FMR LLC has disclosed an 8.3% beneficial ownership in Viatris Inc. (VTRS), amounting to 96,362,102.65 shares. Abigail P. Johnson is also reported as a beneficial owner with sole dispositive power over the same shares and stake percentage. This information comes from a SCHEDULE 13G SEC filing, indicating a passive investment rather than an attempt to control the company.
Lexicon Pharma (Nasdaq: LXRX) swings to $31.8M Q2 2026 loss
Lexicon Pharmaceuticals reported a significant net loss of $31.8 million in Q2 2026, compared to a net income of $3.3 million in the prior-year quarter, primarily due to lower revenues from the absence of substantial licensing income and increased operating expenses. Despite the financial setback, the company highlighted progress in its clinical programs, including the completion of enrollment for its Phase 3 SONATA-HCM trial and anticipated NDA resubmission for ZYNQUISTA in type 1 diabetes. Lexicon also secured a new $100 million loan facility and reported $190.6 million in cash and investments.
Earnings Flash (VTRS) Viatris Inc. Posts Q2 Adjusted EPS $0.69 per Share, vs. FactSet Est of $0.60
Viatris Inc. (VTRS) reported Q2 adjusted EPS of $0.69 per share, surpassing the FactSet estimate of $0.60. The company also announced Q2 revenue of $3.76 billion, exceeding the FactSet estimate of $3.68 billion.
The only FDA-approved dry-eye nasal spray is set to join Harrow later in 2026
Harrow has entered an agreement to acquire global rights to TYRVAYA, the sole FDA-approved nasal spray for dry eye disease, from Viatris. The deal, valued at up to $100 million ($30 million upfront cash and up to $70 million in sales-tied milestones), is expected to close in the second half of 2026 and be financially accretive shortly thereafter. This acquisition expands Harrow's dry eye portfolio, complementing its VEVYE franchise with a differentiated, drop-free treatment option.
Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease
Harrow has acquired global rights to TYRVAYA® (varenicline solution) nasal spray from Viatris Inc. for up to $100 million. This acquisition significantly expands Harrow's dry eye portfolio, complementing its VEVYE franchise with a differentiated, drop-free treatment option for dry eye disease. The deal is expected to close in the second half of 2026 and aims to strengthen Harrow's market position by offering a broader range of therapeutic solutions for dry eye patients.
Viatris Reports Second-Quarter 2026 Financial Results
Viatris Inc. announced strong second-quarter 2026 financial results, with total revenues of $3.8 billion, a 5% reported growth, and Adjusted EBITDA of $1.2 billion, up 8% operationally. The company raised its 2026 financial guidance midpoints, returned approximately $550 million to shareholders, and reduced its gross leverage ratio to 2.9x, while also achieving key pipeline milestones like the U.S. FDA approval of Gwyn Lo TM and completing the sale of its Biocon Limited equity.
Lexicon Pharmaceuticals, Inc. (LXRX) Stock Price, News, Quote & History
Lexicon Pharmaceuticals, Inc. (LXRX) closed at $2.3600, down 3.67%, with after-hours trading showing a further slight decrease. The company, focused on biopharmaceutical products, reported Q2 2026 earnings and has several drugs in development including sotagliflozin (INPEFA, ZYNQUISTA) and new candidates for obesity and neuropathic pain. Analysts have an average target price of $3.77 for LXRX, with recent recommendations including a maintained "Buy" rating from Citigroup.
